Johnson & Johnson is committed to developing groundbreaking therapies for autoimmune diseases caused by autoantibodies and alloantibodies, aiming to improve the lives of millions affected worldwide.
For people living with autoimmune diseases, their condition can cast a constant shadow over nearly every aspect of their lives. It might be the first thing they think about in the morning. It can frequently dominate conversations with family and friends. Each day may bring pain and new limits on activities—all frustrating reminders that the immune system designed to protect them is endangering their health.
While relieving the physical and mental burden of these diseases is difficult, scientists have gained a greater understanding of the intricate underlying pathways that trigger different immune system disorders. Those discoveries have opened doors for developing advanced therapies targeting specific pathways. Immunology leader Johnson & Johnson is specifically building upon decades of innovation to research autoimmune diseases driven by autoantibodies and alloantibodies. Antibodies seek out and kill external invaders such as viruses and bacteria. But in some people, for reasons not fully understood, the body creates pathogenic antibodies—called autoantibodies—to attack its organs and tissues. Likewise, during some pregnancies, genetic differences in the fetus, such as on red blood cells, can trigger alloantibodies that cross the placenta and attack fetal organs and tissues. According to Johnson & Johnson’s team of immunology experts, more than 80 different diseases are classified as auto- and alloantibody diseases, and together they affect nearly 240 million people worldwide. There are limited safe and effective options for treatment, representing an immense unmet need. “There is a tremendous opportunity to drive significant change in how patients live with these diseases,” says Tom Mickelson, Johnson & Johnson Innovative Medicine’s vice-president, global autoantibody portfolio and maternal-fetal commercial leade
AUTOIMMUNE DISEASES THERAPIES JOHNSON & JOHNSON IMMUNOOLOGY TREATMENT
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Unlocking worm strategies: A path to innovative vaccines and therapiesA research team has uncovered a molecular strategy employed by worm parasites (helminths) to evade host immune defenses. This discovery opens new avenues for the development of innovative vaccines and therapies.
Read more »
'Selling Tampa' Star Reportedly Caught Fiance Cheating on Home SurveillanceChad Johnson and Sharelle Johnson together
Read more »
Motley Fool: Johnson & Johnson offers dividends and growthJohnson & Johnson offers a solid earnings track record, as well as a new era of revenue growth down the road.
Read more »
Biden Administration’s Access Model Offers Hope For Cell And Gene TherapiesBiden Administration says that manufacturers of sickle cell gene therapies agree to participate in access model in 2025. Model may expand to include other therapies.
Read more »
New targeted therapies offered to Isle of Man patientsManx Care follows UK recommendations to roll out new treatment options for a range of conditions.
Read more »
Compassionate Use of Experimental Cancer TherapiesProfessor David Kerr discusses the challenges and opportunities of using experimental cancer treatments, highlighting the need for flexible approaches while upholding rigorous clinical standards.
Read more »